Investigating the neurocognitive deficits associated with chronic drug misuse

Current Opinion in Neurobiology

Volumn 11, Issue 2, 2001, Pages 250-257

  Rogers, Robert D ^a   Robbins, Trevor W ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Cambridge   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; CENTRAL STIMULANT AGENT; OPIATE;

ATTENTION; BRAIN CORTEX; COGNITIVE DEFECT; DECISION MAKING; DISEASE ASSOCIATION; DRUG MISUSE; IMAGING; MEMORY; NEUROMODULATION; NEUROPHARMACOLOGY; NEUROPSYCHOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0035312930     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-4388(00)00204-X     Document Type: Review

References (73)

1. Implications of cognitive impairment for the treatment of alcoholism
2. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans
3. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons
4. The biological, social and clinical bases of drug addiction: Commentary and debate
5. Acute effects of cocaine on human brain activity and emotion
6. Relationship between subjective effects of cocaine and dopamine transporter occupancy
7. Cocaine decreases cortical cerebral blood flow but does not obscure regional activation in functional magnetic resonance imaging in human subjects
8. Event-related potential indices of auditory selective attention in dependent amphetamine users
9. Cognitive rehabilitation of chronic alcohol abusers
10. Deprivation state but not nicotine content of the cigarette affects responding by smokers on a progressive ratio task
11. Cannabinoid receptor localization in brain
12. Long-term effects of repeated methamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study
13. The residual neuropsychological effects of cannabis: The current status of research
14. Effects of chronic marijuana use on human cognition
15. Cognitive correlates of long-term cannabis use in Costa Rica men
16. Differential impairments of selective attention due to frequency and duration of cannabis use
17. Do cognitive impairments recover following cessation of cannabis use?
18. Specific attentional dysfunction in adults following early start of cannabis use
19. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication
20. Repeated exposure to Δ9-tetrahydrocannabinol reduces prefrontal cortical dopamine in the rat
21. Cerebellar hypoactivity in frequent marijuana users
22. Brain morphological changes and early marijuana use: A magnetic resonance and positron emission tomography study
23. Effects of frequent marijuana use on brain tissue volume and composition
24. Neuropsychological performance of recently abstinent alcoholics and cocaine abusers
25. Neuropsychological deficits in abstinent cocaine abusers: Preliminary findings after two weeks of abstinence
26. Cognitive effects of cocaine and polydrug abuse
27. Neuropsychological impairment in chronic cocaine abusers
28. Cerebral perfusion and neuropsychological consequences of chronic cocaine use
29. Long-term frontal brain metabolic changes in cocaine abusers
30. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers
31. Cerebral glucose utilization in polysubstance abuse
32. Cocaethylene. What is it?
33. Alcoholism in treatment-seeking cocaine abusers: Clinical and prognostic significance
34. Neuropsychological functioning in cocaine abusers with and without alcohol dependence
35. Dose-related neurobehavioral effects of chronic cocaine use
36. Gender differences in neuropsychological test performance among cocaine abusers
37. Differential effects of cocaine and cocaine alcohol on neurocognitive performance
38. Amphetamine psychosis and psychotic symptoms
39. Dissociating deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms
40. Tryptophan depletion causes a rapid lowering of mood in normal males
41. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
42. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users
43. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers
44. Drug abusers show impaired performance in a laboratory test of decision-making
45. Insensitivity to future consequences following damage to human prefrontal cortex
46. Wisconsin Card Sorting Test performance as a measure of frontal lobe damage
47. Decision making deficits, linked to dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers
48. Orbitofrontal cortex and human drug abuse: Functional imaging
49. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats
50. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys
51. Impaired inhibition of conditioned responses produced by sub-chronic administration of phencyclidine to rats
52. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys
53. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine
54. Brain dopamine in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: Evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations
55. Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: Neurochemical observations
56. Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin in human beings
57. Chronic 3, 4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function
58. Impaired memory function in (±) 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users
59. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users: A controlled study
60. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
61. Recreational use of ecstasy (MDMA) is associated with elevated impulsivity
62. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: Implications for the monoaminergic basis of impulsive behaviour
63. Collaborative neuropsychological study of polydrug users
64. Computerised transaxial tomographic and neuropsychological evaluations in chronic alcohol and heroin abusers
65. Intellectual and neuropsychological functions in young men with heavy and long-term patterns of drug abuse
66. Neuropsychological functioning in opiate addicts
67. Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: Drug and monetary rewards
68. Substance abuse patterns reveal contrasting personality traits
69. Morphine alters the structure of neurons in the nucleus accumbens and neocortex of rats
70. Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli
71. Addiction, a disease of compulsion and drive involvement of the orbitofrontal cortex
72. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: Implications in addiction